Overview

Third Dose of COVID-19 Vaccine in LTCF Residents

Status:
Not yet recruiting
Trial end date:
2022-04-15
Target enrollment:
0
Participant gender:
All
Summary
This study is a multi-centre, blinded, randomized controlled trial. LTCF residents ≥65 years who have had two doses of mRNA-1273 vaccine will be randomized to vaccination with a third dose of mRNA-1273 vaccine or to vaccination with a control (Prevnar-13 vaccine).
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Mark Loeb
Treatments:
Heptavalent Pneumococcal Conjugate Vaccine
Vaccines
Criteria
Inclusion Criteria:

- A LTCF resident will be eligible if they are ≥ 65 years and have received two doses of
mRNA-1273 vaccine

Exclusion Criteria:

- Immunocompromised individuals due to known or suspected immunodeficiency or due to
receipt of immunosuppressive medication (e.g., steroids, biologics)

- Having had a severe adverse reaction (e.g., anaphylactic allergy) to mRNA-1273 or
pneumococcal Prevnar-13 vaccine

- Having received pneumococcal polysaccharide vaccine within 12 months.